Key regions: France, India, United Kingdom, South Korea, Japan
The Eastern European market for Multiple Sclerosis (MS) Drugs is witnessing significant growth due to various factors.
Customer preferences: Patients in Eastern Europe are increasingly opting for MS drugs due to the rising prevalence of the disease in the region. Additionally, the availability of advanced medical facilities and infrastructure, coupled with the rising awareness regarding MS diagnosis and treatment, is driving the demand for MS drugs.
Trends in the market: The MS drugs market in Eastern Europe is witnessing a shift towards the use of advanced therapies such as monoclonal antibodies and oral treatments. This trend is driven by the increasing availability of these drugs in the region, along with the growing preference for more convenient and effective treatment options. Moreover, the rising demand for biosimilars is also expected to drive the growth of the MS drugs market in Eastern Europe.
Local special circumstances: The Eastern European market for MS drugs is characterized by a high level of fragmentation, with a large number of small and medium-sized players operating in the region. This has led to intense competition among players, with companies focusing on product innovation and differentiation to gain a competitive edge. Additionally, the region has a large population of young adults, who are at a higher risk of developing MS, further driving the demand for MS drugs.
Underlying macroeconomic factors: The Eastern European market for MS drugs is expected to grow at a steady pace due to favorable macroeconomic factors such as rising healthcare expenditure, increasing government support for healthcare infrastructure development, and a growing focus on research and development activities in the region. Additionally, the increasing adoption of advanced medical technologies and the growing awareness regarding MS diagnosis and treatment are expected to further drive the growth of the MS drugs market in Eastern Europe.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
